Pluri (PLUR) Non-Current Deffered Revenue (2011 - 2015)
Pluri (PLUR) posted quarterly Non-Current Deffered Revenue of $2.4 million for Q3 2015, down 13.77% year-over-year from $2.8 million in Q3 2014, and down 3.85% quarter-over-quarter from $2.5 million in Q2 2015.
Pluri (PLUR) Non-Current Deffered Revenue (2011 - 2015) Analysis & Trends
Pluri (PLUR) has reported Non-Current Deffered Revenue for 5 consecutive years, with $2.4 million the latest figure, recorded in Q3 2015.
- In Q3 2015, Non-Current Deffered Revenue fell 13.77% year-over-year to $2.4 million; the TTM figure through Sep 2015 stood at $2.4 million (down 13.77% YoY), while the FY2015 annual figure was $2.5 million, down 13.31% from the prior year.
- Non-Current Deffered Revenue declined to $2.4 million in Q3 2015 per PLUR's latest filing, from $2.5 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $3.9 million in Q3 2011 and bottomed at $3116.0 in Q4 2012.
- Historically, Non-Current Deffered Revenue has averaged $2.9 million across 5 years, with a median of $3.0 million in 2013.
- Annual changes were most pronounced in 2012 — Non-Current Deffered Revenue plunged 99.92% — and 2013, when it jumped 97332.61%.
- Pluri's Non-Current Deffered Revenue stood at $3.7 million in 2011, then slumped by 99.92% to $3116.0 in 2012, then surged by 97332.61% to $3.0 million in 2013, then fell by 12.48% to $2.7 million in 2014, then slipped by 10.69% to $2.4 million in 2015.
- Business Quant data shows PLUR's Non-Current Deffered Revenue at $2.4 million in Q3 2015, $2.5 million in Q2 2015, and $2.7 million in Q4 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 2.37 Mn |
| Jun 30, 2015 | 2.47 Mn |
| Dec 31, 2014 | 2.66 Mn |
| Sep 30, 2014 | 2.75 Mn |
| Jun 30, 2014 | 2.85 Mn |
| Mar 31, 2014 | 2.94 Mn |
| Dec 31, 2013 | 3.04 Mn |
| Sep 30, 2013 | 3.13 Mn |
| Jun 30, 2013 | 3.23 Mn |
| Mar 31, 2013 | 2.92 Mn |
| Dec 31, 2012 | 3,116.00 |
| Sep 30, 2012 | 3.31 Mn |
| Jun 30, 2012 | 3.51 Mn |
| Mar 31, 2012 | 3.46 Mn |
| Dec 31, 2011 | 3.69 Mn |
| Sep 30, 2011 | 3.92 Mn |